Yamada O, Hatake K, Tanimoto M, Ishiyama T, Ohno R, Shirakawa S, Horiuchi A, Tomonaga M, Ohta K
Dept. of Medicine, Kawasaki Medical School.
Gan To Kagaku Ryoho. 1994 Sep;21(12):1981-9.
Efficacy and safety of tretinoin (all-trans retinoic acid, ATRA, Ro01-5488) for refractory and relapsed acute promyelocytic leukemia were studied by multi-institutional study in Japan. 22 out of 27 (81.5%) patients with previously untreated who were intolerable to chemotherapy, relapsed and refractory were achieved CR. And 4 out of 11 (36.4%) in relapsed patients who received ATRA remission induction therapy previously responded. Side effects, such as dryness of the lip and skin, headache, increase of triglyceride, beta-lipoprotein and lactate dehydrogenase, were observed in 36 of 41 eligible patients (87.8%) but these were well tolerated. In addition to these, hyperleukocytosis in 4 cases and retinoic acid syndrome in 3 cases were observed. However, all patients were prescribed tretinoin again by adequate management.
在日本，通过多机构研究对维甲酸（全反式维甲酸，ATRA，Ro01 - 5488）治疗难治性和复发性急性早幼粒细胞白血病的疗效和安全性进行了研究。27例先前未经治疗且对化疗不耐受、复发和难治的患者中有22例（81.5%）达到完全缓解（CR）。先前接受过ATRA缓解诱导治疗的11例复发患者中有4例（36.4%）有反应。41例符合条件的患者中有36例（87.8%）观察到了副作用，如嘴唇和皮肤干燥、头痛、甘油三酯、β脂蛋白和乳酸脱氢酶升高，但这些副作用耐受性良好。除此之外，还观察到4例高白细胞血症和3例维甲酸综合征。然而，通过适当的处理，所有患者都再次接受了维甲酸治疗。
